Abstract:Jared Silver, 1 Andrea Steffens, 2 Benjamin Chastek, 2 Arijita Deb 3 1 Medical Affairs, GSK, Durham, NC, USA; 2 Optum, Eden Prairie, MN, USA; 3 Value, Evidence and Outcomes, GSK, Upper Providence, PA, USA Correspondence: Arijita Deb, Value, Evidence and Outcomes, GSK, 1250 S Collegeville Road, Upper Providence, PA, 19426, USA, Tel +1 267 377-5717, Email Purpose: Real-world data on mepolizumab in patients with severe asthma and allergic and non-allergic phenotypes are limited. This study investigated the effectiveness of mepolizumab treatment in patients with severe asthma with allergic and non-allergic phenotypes. Patients and Methods: This retrospective cohort study (GSK ID: 214148) used administrative claims data from the Optum Research Database. Eligible patients were ≥ 6 years of age with asthma and had ≥ 2 mepolizumab claims post-index. Index date was the first mepolizumab claim/administration (January 2016–December 2018). Patients were divided into two cohorts: allergic and non-allergic asthma, based on diagnosis codes, medication use and lab test results. Outcomes included the rate of asthma-related exacerbations and oral corticosteroid (OCS) use during the 12 months before (baseline period) and 12 months after (follow-up period) mepolizumab initiation. Study ended in December 2019. Results: Overall, 240 (44.6%) and 298 (55.4%) patients were included in the allergic and non-allergic asthma cohorts, respectively. Mean (standard deviation [SD]) counts of asthma-related exacerbations were significantly reduced from baseline to follow-up in both the allergic and non-allergic asthma cohorts (3.2 [2.5] to 2.1 [2.1], p < 0.001 and 2.5 [2.2] to 1.7 [1.9], p < 0.001, respectively). The mean number of OCS pharmacy claims was significantly decreased by 33.3% and 41.4% from baseline to follow-up in the allergic and non-allergic cohorts, respectively (p < 0.001); mean daily OCS dose significantly decreased by 30.6% and 45.4%, respectively (p < 0.001) as well as the mean number of OCS bursts, which decreased by 44.9% and 41.8%, respectively (p < 0.001). No significant differences were observed between cohorts in reductions in asthma exacerbations, counts of OCS pharmacy claims or OCS bursts (baseline to follow-up). Conclusion: Mepolizumab significantly reduced asthma exacerbations and OCS use in patients with allergic and non-allergic asthma, suggesting that mepolizumab provides real-world benefit in severe asthma irrespective of whether a patient has an allergic phenotype. Keywords: severe asthma, phenotype, exacerbation, oral corticosteroid Severe asthma is characterized by treatment with high-dose inhaled corticosteroids (ICS) in addition to a second controller and/or systemic corticosteroids (SCS), including oral corticosteroids (OCS). 1 However, symptoms may remain uncontrolled leading to frequent asthma exacerbations requiring short-acting ß 2 -agonist (SABA) and OCS use, emergency treatment, or hospitalization. 1,2 Severe asthma can be classified by phenotype including those with elevated sputum and/or blood eosinophil counts (severe asthma with an eosinophilic phenotype) or sensitivity to environmental allergens plus elevated immunoglobulin E (IgE) levels (severe allergic asthma). 3–5 These phenotypes share features including being mechanistically driven by type 2 inflammation and the presence of elevated eosinophil counts. 5 Approximately three-quarters of patients with severe asthma with an eosinophilic phenotype also have an allergic phenotype. 6 Treatments targeting the common mechanisms underlying phenotypes, such as elevated eosinophil counts, plausibly provide benefit across asthma phenotypes. 5 Mepolizumab is a humanized monoclonal antibody approved in Europe and the USA as an add-on therapy for the treatment of severe asthma. 7,8 By specifically targeting interleukin (IL)-5, a cytokine that promotes differentiation, activation, and eosinophil survival, mepolizumab enables a precision medicine approach to eosinophilic disease. 9–11 Mepolizumab efficacy in patients with severe asthma is well documented in clinical trials, 12–14 post hoc analyses of clinical trials, 15,16 and real-world studies. 17–20 However, most data on mepolizumab efficacy in patients with and without allergic phenotypes is limited to clinical studies. Post hoc analyses of the DREAM (NCT01000506), MENSA (NCT01691521), and MUSCA (NCT02281318) clinical trials demonstrated similar clinical benefit of mepolizumab in patients with severe asthma irrespective of atopic status, prior omalizumab use, IgE level and sensitivity to particular allergens.<s -Abstract Truncated-

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies

Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia

Mepolizumab in patients with asthma and features of COPD: A MENSA/MUSCA post hoc analysis

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

Efficacy and Safety of Omalizumab for the Treatment of Pediatric Allergic Asthma: a Retrospective Multicenter Real-World Study in China

Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis

Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

The influence of Adherence to inhaled Corticosteroids (ICS) on treatment Response to mepolizumab treatment in severe Eosinophilic asthma

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders